XOMAP News and Press, XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock From 05/09/23

First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 fin...

2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378 million, net, in milestones plus mid-single digit to low teens royalties, net, from Org...

Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).  First five months of sales in the U.S. and initial sales in Japan resulted in a $0.5 million c...

These July sample selections are the current top positive/negative forensic stocks out of 8,000 stocks based on combined scores from four top forensic algorithms. The January Positive Forensic portfolio is beating the S&P 500 by +1.59% YTD. The Negative portfolio is beating by +13...

While XOMA offers an investment into an important sector of healthcare, drug revenue royalties, the story is just beginning. From first glance, years of losses and flat revenues look poor, but something special is hidden underneath. Those looking to get in before the story plays o...

Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022.  Rezolute has announced its intention to move RZ358 into Phase 3 clinical development. Roche’s ...

The following slide deck was published by XOMA Corporation in conjunction with this event. For further details see: XOMA (XOMA) Investor Presentation - Slideshow

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

XOMA Preferred Shares Series A (NASDAQ:XOMAP) declares $0.5391/share quarterly dividend, in line with previous. Forward yield 8.21% Payable Jan. 18; for shareholders of record Jan. 4; ex-div Jan. 3. See XOMAP Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: ...

Half of my retirement savings is invested in two sectors. It's important to match your investment allocations to what will meet your goals and needs. Income investing provides extremely high levels of flexibility. For further details see: I Put Half Of My Retirement Savi...